MPLT NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

MapLight Therapeutics, Inc. Common Stock · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 13.02 USD
-64.4% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is -47.8% below the Trend Line and sits at 12.5% of its 52-week range. The latest completed week returned -64.4%, after a -64.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 50/100 conviction, while the latest news-sentiment score is 52/100. Near-term considerations: earnings are due in 11d.

Setup score 47 out of 100
Latest Close 13.02 USD 31 Jul 2026
1W Return -64.4% latest completed week
4W Return -64.9% short-term follow-through
12W Return -52.5% quarterly tape
Trend Breadth 27.5% 11 of 40 weeks active
Volume Ratio 6.0x vs 13-week average
What is working
  • The trend backdrop is active with a 11-week active streak.
  • Activity pressure is positive on the latest completed week.
  • Volume is elevated versus the 13-week average, confirming attention.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • 10 reversal markers appear in the recent smart-money tape.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -64.4% Latest completed week; four-week move -64.9%. Indicator stack 53/73 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 50/100 conviction; expected move 33.2%. News sentiment 52/100 67 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is -47.8% below the Trend Line and sits at 12.5% of its 52-week range. The latest completed week returned -64.4%, after a -64.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 6.0x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8712-week average 0.73

12-week confirmation

Trend active11/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.87Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers1010 reversal markers

No recent accumulation markers. 10 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -64.9% over four weeks, -52.5% over 12 weeks, and - over one year. The current trend has remained active for 11 consecutive weeks.

Performance by holding period

1W-64.4%
4W-64.9%
12W-52.5%
26W-26.4%
52W-
Active trend streak11 weeks
Active weeks in one year11
Trend breadth27.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.17Latest activity-pressure read.
Pressure change19.0%Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 61% Model confidence 58%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength79/100Blend of value, momentum, and quality. Underlying universe rank 22; rank 1 is best.
Value64/100Relative valuation strength. Underlying universe rank 37; rank 1 is best.
Quality63/100Profitability and accounting quality. Underlying universe rank 38; rank 1 is best.
Momentum65/100Medium-term price momentum. Underlying universe rank 36; rank 1 is best.
Growth65/100Revenue and earnings growth. Underlying universe rank 36; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-10.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-42.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-28.6%
Net share repurchases relative to market value.
Shareholder yield
-28.6%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

MPLT shows volatility options pressure with a 50/100 conviction score, put-call volume ratio of 9.72, expected move of 33.2%, and Sharemaestro trend signal active.

Conviction50/100
Expected move33.2%
Put/call volume9.72
Pressure-75
Speculation41
Volatility96
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 67 relevant articles.

16 positive · 39 neutral · 12 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move33.2%Nearest-chain priced movement where available.
52-week drawdown-67.8%Distance below the 52-week high.
13-week volatility18.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher16 of 2610 weeks finished lower.
Best week+26.3%Week of 10 Apr.
Worst week-64.4%Week of 31 Jul.
Latest week-64.4%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains7
Flat weeks0
Modest losses5
Sharp losses5
Recent vol18.8%13-week weekly-return volatility.
Base vol14.2%52-week weekly-return volatility.
Up/down split20/19Count of positive and negative weeks in the 52-week window.
Average skew9.1% / -8.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape53/100

Trend, activity pressure, participation, and risk combine to a 53/100 tape read.

 Indicator analysis60/100

Latest 12-week confirmation: trend 11/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.87; 10 reversal markers Factors67/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 93; Small Cap Core rank 44 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Options35/100

MPLT shows volatility options pressure with a 50/100 conviction score, put-call volume ratio of 9.72, expected move of 33.2%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 33.2% Sentiment52/100

Weighted news tone is neutral across 67 relevant articles.

Maplight Therapeutics (NASDAQ:MPLT) Shares Down 9.2% - What's Next? Insiders50/100

No recent insider transaction evidence is stored.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202613.02 USD-64.4%24.93 USD22.92 USD1.17-20.9MOn
24 Jul 202636.56 USD-3.5%25.06 USD23.17 USD1.38-2.3MOn
17 Jul 202637.87 USD-3.7%24.44 USD22.82 USD1.44-3.3MOn
10 Jul 202639.32 USD6.0%23.86 USD22.42 USD1.28-3.0MOn
3 Jul 202637.09 USD11.4%23.24 USD21.95 USD0.99-1.7MOn
26 Jun 202633.28 USD15.5%22.62 USD21.51 USD0.92-3.6MOn
19 Jun 202628.82 USD3.9%21.97 USD21.17 USD0.78-2.3MOn
12 Jun 202627.75 USD-0.9%21.47 USD20.93 USD0.85-1.3MOn
5 Jun 202628.01 USD-4.4%21.02 USD20.72 USD0.98-1.8MOn
29 May 202629.31 USD1.9%20.61 USD20.49 USD1.03-1.4MOn
22 May 202628.75 USD0.1%20.19 USD20.19 USD1.05-1.2MOn
15 May 202628.73 USD4.9%-19.90 USD0.80-1.1MOff
8 May 202627.40 USD-10.7%-19.58 USD--1.4MOff
1 May 202630.70 USD3.2%-19.29 USD--1.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.